Further, BCL2 in module 2 was a therapeutic target for chronic lymphocytic leukemia since it can regulate lymphocyte in blood by hindering cell apoptosis (Ruefli-Brasse and Reed, 2017; Tahir et al., 2017) and PGD in module 5 was related with human cervical carcinoma (Lee et al., 2014). This evidence concerns the gene BCL2 and cervical carcinoma.